PKN605

Small molecule

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Atrial Fibrillation
NCT07217067 · Novartis Pharmaceuticals
2025-10-28 – 2027-09-09 · Atrial Fibrillation
What this study did
Phase 1 (1)
Other / comorbidity
NCT07797322 · Novartis Pharmaceuticals
2026-10-01 – 2027-03-02 · Participants With Moderate and Severe Renal Impairment and Healthy Participants
What this study did

Competitive landscape

Other HDAC6 (Histone deacetylase 6) drugs

CKD-506. Compare all 2 HDAC6 (Histone deacetylase 6) drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
PKN605: this drugPhase 2Small moleculeHDAC6 (Histone deacetylase 6)not yet gradedNo reviewed efficacy summary
CKD-506
Phase 2(overall)
Small moleculeHDAC6 (Histone deacetylase 6)Partial signal
NCT04204603: Primary endpoint, change from baseline in DAS28(CRP) at week 12 (full analysis set, n=121): placebo -1.2, CKD-506 200 mg -1.0, 400 mg -1.3, 600 mg -1.2; pre-specified dose-response trend test p > 0.5 (EudraCT 2018-001377-24 posted results). missed

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow PKN605 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
March 2027 (1)
Phase 1Participants With Moderate and Severe Renal Impairment and Healthy ParticipantsRecruiting
Est. primary completion 2027-03-01 · NCT07797322 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Atrial FibrillationRecruiting
Est. primary completion 2027-09-09 · NCT07217067 · CT.gov ↗
What to watch

See the full readout calendar ↗